newsfilter
← Latest News
GlobeNewswire·

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now considered to be the optimal